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AngiogenesisInterleukin (IL)-6, -4, and -8 levels have been elevated in most patients suffering from prostate, breast, or
colon cancer. There is a large body of evidence suggesting that chronic inﬂammation is one of the etiologic
factors in these tumors. IL-6 is a multifunctional cytokine which is known to inﬂuence proliferation,
apoptosis, and angiogenesis in cancer. Its transcription factor STAT3 is known as an oncogene that is
constitutively phosphorylated in these malignancies. However, IL-6-induced STAT3 phosphorylation may
result in growth arrest. IL-6 activation of androgen receptor in prostate cancer may yield either tumor cell
proliferation or differentiation. Prolonged treatment with IL-6 results in generation of sublines which
express a more malignant phenotype. Therapy options against IL-6 have been established and the antibody
siltuximab has been applied in preclinical and clinical studies. Recently, investigations of the role of
suppressors of cytokine signaling have been carried out. IL-4 and -8 are implicated in regulation of apoptosis,
migration, and angiogenesis in cancers associated with chronic inﬂammation. All cytokines mentioned above
regulate cellular events in stem cells. These cells could not be targeted by most conventional cancer
therapies..
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
The role of chronic inﬂammation in human carcinogenesis is an
issue of high interest. Althoughmany publications have demonstrated
that there are similarities in the expression of oncogenes and tumor
suppressors between chronic inﬂammatory and pre-malignant
lesions and cancer tissue, experimental research in this ﬁeld is still
in its early stages. The investigations may be facilitated, however, if
more animal models are developed. They may allow a better
understanding of causal changes in cell cycle progression, apoptosis,
and initiation of angiogenesis, migration, and invasion caused by pro-
inﬂammatory cytokines and respective transcription factors and/or
their inhibitors. Although there are many cancers in which pro-
inﬂammatory cytokines play a role in pathogenesis, the focus of this
review will be on those of prostate, breast, and colon. The most
important cytokines associatedwith inﬂammation, interleukins (IL)-6,
-4, and -8 will be discussed in the manuscript.2. Cytokine signal transduction in benign and malignant tissue
IL-6 is a multifunctional cytokine which binds to the receptor
composed of the ligand-binding subunit gp80 and ubiquitously
expressed signal-transducing subunit gp130. Following this binding,
there is a phosphorylation of Janus kinases (JAK) after which signaltransducer and activator of transcription (STAT) factor-3 is phos-
phorylated and translocated to the nucleus. STAT3 phosphorylation is
a rapid process with the peak observed in most cells between 15 and
30 min of the treatment with the cytokine. However, in addition to
the JAK-STAT signaling pathway other signal transduction cascades
may be activated. Thus, treatment with IL-6 may lead to phosphor-
ylation of mitogen-activated protein kinases p44 and p42 or Akt in
target tissues; reviewed in [1]. Continuous activation of the signaling
pathway of JAK/STAT is prevented by suppressors of cytokine
signaling (SOCS) and protein inhibitors of activated STAT (PIAS).
The role of selected SOCS in regulation of cellular events in prostate
cancer will be discussed later in this review.
IL-4 is a cytokine which, under normal conditions, acts as an anti-
inﬂammatory compound thus being responsible for the homeostasis
of the immune system. IL-4 may however act through the Akt
pathway thus promoting the survival of cancer cells [2]. STAT6 is
responsible for mediation of the anti-apoptotic action of IL-4 which is
reﬂected in induction of expression of Bcl-2 and Bcl-x proteins.
IL-8 is implicated in a variety of cellular processes that enhance
migration and invasion [3]. It has an important role in angiogenesis
through stimulation of endothelial cell migration and suppression of
programmed cell death. It is also known as CXCL8 and is produced by
endothelium cells, monocytes, epithelial cells, and ﬁbroblasts.
Expression of IL-8 is under control of the nuclear factor kappa B and
it may also increase under hypoxic conditions and after stimulation by
activating protein (AP)-1. Two G protein-coupled receptors, CXCR-1
and -2, are activated after IL-8 treatment. The binding afﬁnity of IL-8 is
higher for CXCR-1 than for CXCR-2.
Fig. 1. Elevated activity of up-stream factors which control IL-6 expression in cancers.
Elevated IL-6 levels in tumor result from coordinated action of NF kappa B, AP-1, TGF-
beta, and loss of tumor suppressor retinoblastoma.
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The recognition that IL-6 is increasingly expressed in sera of
patients with metastatic carcinoma of the prostate has greatly
stimulated research in the ﬁeld. In the initial publication by the J.
Simons' group, high levels of the cytokine were also measured in the
supernatants from cells which represent advanced prostate cancer [4].
Therefore, in subsequent studies the cells which produce IL-6 were
identiﬁed in the specimens obtained from patients with prostate
diseases [5]. In the benign prostate, IL-6 expression was detected in
basal cells. Most tumor cells were found to be IL-6-positive. The
presence of the IL-6 receptor in tumor tissues has indicated that the
cytokine's signaling pathways are operative in most if not all patients
withmalignant prostate disease. Interestingly, high levels of IL-6 were
measured in the supernatants from stromal cultures also. This fact
provides additional support for the concept established more than
two decades ago according to which stromal paracrine loops critically
inﬂuence the events in cancer.
Investigations on regulation of cellular events by IL-6 in prostate
cancer have been mostly focused on established cell lines. It is
particularly interesting to note in this context that different results on
regulation of proliferation of androgen-sensitive LNCaP cells by IL-6
were obtained. These cells are one of themost frequently usedmodels
in prostate cancer research. The treatment of cells with the cytokine
resulted in either inhibition or stimulation of proliferation [6,7]. It is
known that LNCaP cells change their properties with passaging and,
for that reason, it may be difﬁcult to compare some of the cells
cultured in different laboratories. IL-6 treatment of LNCaP cells is
associated with increased phosphorylation of STAT3. Additional work
to clarify the differences in regulation of growth of androgen-
sensitive prostate cancer cells is needed, however some explanations
may be provided on the basis of research in melanoma. STAT3
phosphorylation in melanoma models may be inﬂuenced by relative
density of cells seeded in individual experiments [8]. An interesting
and well-supported explanation regarding those different results
with implications in carcinoma of the prostate was offered recently by
Barbieri and colleagues [9]. Those authors showed in a breast cancer
model that constitutive activation of the transcription factor is mainly
associated with proliferative effects. In contrast, IL-6-induced effect
on STAT3 phosphorylation may result in growth inhibition. IL-6-
caused growth inhibition in the LNCaP cell model is accompanied by
neuroendocrine differentiation as manifested by changes in mor-
phology, in particular extended processes and increased expression of
neuroendocrine markers [10]. Neuroendocrine cells in prostate
cancer are considered indicators of bad prognosis. They secrete a
number of peptides which inﬂuence growth of adjacent epithelial
cells in a paracrine manner. IL-6-caused growth-inhibitory effects in
the LNCaP model could be explained by the negative regulation of
cyclin-dependent kinases and cyclins which are responsible for G1/S
cell cycle progression [11].
For obvious clinical reasons, it became interesting to study changes
that may occur during long-term treatment of cells with IL-6. LNCaP
cells are a good candidate for such experimental studies because the
parental cell line is inhibited by the cytokine. It was hypothesized in
our laboratory that prostate cancer cells which are cultured over a
long period of time may display changes in activation of signaling
pathways. LNCaP cells, after prolonged culture in medium supple-
mentedwith IL-6, acquired a growth advantage in vitro and in vivo and
develop an IL-6 autocrine loop. Importantly, the expression of tumor
suppressors was strongly diminished and the expression of molecules
which drive cell cycle progression increased in the newly developed
prostate cancer model LNCaP-IL-6+. In terms of activation of
signaling pathways, LNCaP-IL-6+ cells showed a higher expression
and constitutive activity of mitogen-activated protein kinases,
whereas in the parental and control cells exogenous IL-6 induced
phosphorylation of STAT3.It was also observed that long-term treatment of cells with IL-6
leads to a strongly reduced expression of androgen receptor (AR) [12].
This is in contrast to the short-term treatment in which IL-6 increased
expression and activity of AR [13,14]. In LNCaP cells, the expression of
the AR downstream protein prostate-speciﬁc antigen (PSA) was up-
regulated by IL-6 in parallel with growth inhibition [13]. Thus, it was
concluded that non-steroidal activation of AR may result in differen-
tiation of tumor cells. In contrast, the growth-promoting effect of IL-6
which was dependent on the AR was observed in MDA PCa 2b cells
[15]. The reasons for differences in growth regulation between LNCaP
and MDA PCa 2b cells have not been clariﬁed so far. One has to
consider the fact that AR signaling is rather complex and the cofactors,
coactivators and corepressors, have an important role in the
modulation of responses in a cell type-dependent manner. There is
a large number of AR-associated proteins which inﬂuence the
responsiveness to non-steroidal regulators.
The reasons for IL-6 up-regulation in carcinoma of the prostate
have also been investigated. It seems that this effect is a result of a
complex interplay between several proteins, in particular transform-
ing growth factor-beta (TGF-beta) and the members of the AP-1
complex [16,17]. TGF-beta is an important molecule in regulation of
cellular events in prostate cancer. Although it inhibits the growth of
epithelial cells in culture, it promotes tumor progression through
increased invasion, angiogenesis, and suppression of the immune
response. In addition, the loss of the tumor suppressor retinoblastoma
in prostate cancer tissue contributes to increased expression of IL-6
[18] (Fig. 1).
In AR-negative prostate cancer cells, IL-6 is known as an inhibitor
of apoptosis [19]. This effect on apoptosis is mediated by increased
phosphorylation of Akt, a protein which is highly expressed in
prostate cancer and is an established bad prognostic factor.
More recently, the studies in prostate cancer became focused on
the soluble IL-6 receptor which is responsible for trans-signaling. The
soluble IL-6 receptor is derived either by alternative splicing or
shedding of the membrane receptor. The complex IL-6/soluble IL-6
receptor is able to initiate signal transduction even in the absence of
the membrane receptor. Classic and trans-signaling may synergisti-
cally enhance the cellular effect of IL-6. Interestingly, IL-6 trans-
signaling is mainly involved in the regulation of invasion in prostate
cancer [20]. Mechanistic explanation for this phenomenon could be
found in down-regulation of the tumor suppressor maspin by the
soluble IL-6 receptor. In contrast, IL-6 trans-signaling diminishes
prostate cancer cell proliferation.
Obvious disregulation of IL-6 expression in prostate and pro-
survival effects clearly indicated that the cytokine is a target for
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siltuximab (CNTO 328) has been used. This chimeric murine-human
monoclonal antibody caused heterogenous effects in vitro and in vivo
[21,22]. This is not surprising because prostate cancer is known for its
heterogeneous nature and it is unlikely that a single agent will be
effective in most of the patients who failed therapy. The most
prominent effects in vivo were observed in PC-3 and LuCaP 35
xenografts in which the antibody delayed the tumor progression
[21,23]. In a clinical phase II study whose results were reported
recently, it was observed that the antibody has biological activity in
patients previously treated with chemotherapy in prostate cancer
(docetaxel) as evidenced by reduced levels of C-reactive protein [24].
However, clinical activity was not noted in that paper. Two out of 31
patients had PSA response and none of the study patients presented
with a clinical response according to RECIST (Response Evaluation
Criteria in Solid Tumors). One has to consider the fact that
monotherapy in patients with advanced tumors is unlikely to be
successful. On the basis of those data by Dorff and colleagues, it may
be reasonable to combine the anti-IL-6 therapy with other established
or experimental treatments in prostate cancer.
An important new area for research in prostate cancer is
expression and function of SOCS. These proteins are known in several
cancers as tumor suppressors, however their function in prostate
cancer appears to be different. In our initial study, it was shown that
SOCS-3 whose expressionwas detected in the cell lines in which there
is no phosphorylation of STAT3 and in specimens from patients with
prostate cancer antagonizes anti-proliferative and pro-apoptotic
effects of cAMP [25]. Puhr and associates were able to demonstrate
that inhibition of SOCS-3 expression, achieved by siRNA, leads to an
increased cell death and that the process is modulated by the Bcl-2
protein [26]. On the other hand, SOCS-3 could be induced by basic
ﬁbroblast growth factor. In this situation, it inhibits proliferative and
migratory effects of the mitogen-activated protein kinase pathway
[27]. SOCS-3 could also be induced by androgens. It antagonizes the
hormonal effects on proliferation and migration [28]. Taken together,
these data indicate that SOCS-3 effects in prostate cancer should be
examined further in appropriate in vivo models. Another member of
the same family, SOCS-1, is highly expressed in prostate cancer,
however it exhibits anti-proliferative properties by inhibition of
expression of cyclin-dependent kinases and cyclins [29].Fig. 2. Autocrine and paracrine IL-6 loops in prostate cells. Both epithelial and stromal cells ex
stromal cells' IL-6. In contrast, tumor cells acquire the ability to produce IL-6 and may regula
prostate cancer therapies.4. Anti-apoptotic and angiogenic effects of interleukins-4 and -8
in prostate cancer
The levels of another cytokine which will be discussed in this
review, IL-4, are elevated in sera of patients with prostate cancer [30].
Similarly to IL-6, IL-4 also activates AR in LNCaP cells and increases
PSA expression [31]. This cytokine is considered to be anti-apoptotic
since it is a potent stimulator of the Akt pathway in prostate cancer
cells. For AR activation by IL-4 in prostate cancer, nuclear factor kappa
B, the major regulator of cytokine expression, seems to be required
[32]. More recent studies indicate that IL-4 is implicated in regulation
of fatty acid amide hydrolase, an enzyme whose expression has been
correlated with prostate cancer severity [33].
Earlier studies on IL-8 in prostate cancer were carried out with the
purpose to provide additional diagnostic information. IL-8 serum
levels also correlated with prostate cancer stage and allowed
differentiation between benign and malignant disease [34]. IL-
8 expression in prostate cancer is regulated by the transcription
factor early growth response-1 [35]. NF kappa B binding site is
important for this up-regulation of IL-8. IL-8 is also produced by
prostate stromal cells in response to IL-1 [36]. Again, this is another
example of how stromal cytokines may be important in regulation of
events that lead to tumor development and progression.
In contrast to IL-6 whose effects in prostate cancer may be both
pro- and antitumorigenic, IL-8 is a strong inducer of angiogenesis and
metastasis. The effect of IL-8 on formation of new blood vessels is
mediated through induction of matrix metalloproteinase-9 [37].
Importantly, IL-8 is an inhibitor of TRAIL-based apoptosis and this
effect is achieved through regulation of c-FLIP [38]. This ﬁnding is
particularly important because TRAIL has a potential in tumor therapy
as an agent which selectively targets malignant cells.
Most importantly, IL-8, similarly as IL-6 and IL-4, up-regulates AR
activity. It was shown that this activation leads to enhanced tumor
growth in vitro and in vivo [39]. One of the IL-8 target genes in prostate
cancer is cyclin D1 [40]. Overexpression of IL-8 decreases the efﬁcacy
of the anti-androgen bicalutamide in antagonizing androgenic effects
in tumor cells and promotes androgen-independent tumor growth
[41]. On the basis of those ﬁndings, IL-8 has been considered a target
for novel therapies in carcinoma of the prostate. IL-8 endogenous
levels were depleted in prostate cancer cells by siRNA and apoptosispress IL-6 and its membrane receptor. In benign tissue, epithelial cells are inﬂuenced by
te growth processes in an autocrine or paracrine manner. Thus, IL-6 is a target for novel
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sensitive to the chemotherapeutic agent docetaxel. Experimental
approaches increasing the sensitivity to docetaxel are important
because the clinical beneﬁt in most cases is 2–3 months extended
survival only. However, there has been a limited application of anti-
IL-8 approaches in prostate cancer so far.
5. Interleukin-6 in breast cancer: effect on stem and tumor cells
All three cytokines discussed in the previous chapters are also
implicated in breast tumorigenesis and development of chemother-
apy resistance [43]. Importantly, it was shown that one of the best
studied oncogenes Src induces transformation and self-renewal of
immortal cells via an epigenetic switch which involves NF kappa B,
Let7 miRNA, and IL-6 [44]. Therefore, one could consider application
of anti-IL-6 antibodies in order to target cancer stem cells. The role of
stem cells in prostate and breast carcinogenesis is of substantial
interest. It has been hypothesized that inability of conventional tumor
therapies to target stem cells is a reason for tumor recurrence.
The up-regulation of IL-6 in breast cancer is, similarly as in prostate
cancer, mediated by NF kappa B and AP-1 transcription factors [45]. It
was reported that this regulation is particularly important in
mammary cancer cell lines with enhanced metastatic potential. The
expression of IL-6 in mammary cancer was also enhanced by aryl
hydrocarbon receptor activation [46], in addition to treatment with
IL-1beta or phorbol ester. For this reason, aryl hydrocarbon receptor
could be considered a potential target for modulation of IL-6
expression. In concordance with patient data published in prostate
cancer, it was demonstrated that circulating IL-6 levels predict worse
survival in metastatic breast cancer [47]. High levels of serum IL-6
have independent prognostic value. Breast cancer cells have the
ability to produce IL-6 and autocrine cytokine loops have been
reported [48]. Although under certain conditions IL-6 may inhibit
growth of estrogen receptor-positive tumor cells, growth-stimulatory
autocrine and paracrine regulations have been documented [49,50].
IL-6 signals may be potentiated by interaction between the IL-6
receptor and tyrosine kinase receptors [50]. Thus, this cooperation
between the cytokine and growth factor receptors may result in
synergistic biological responses.
Stromal cells are a rich source of IL-6 in the breast and the cytokine
produced by them is implicated in regulation of migration and
invasion [51]. IL-6 production in those cells depends on the pathway
of coﬁlin-1, a regulator of actin dynamics.
There is considerable evidence linking the activation of STAT3 by
IL-6 and the regulation of cellular events in breast tumor models. As
mentioned before, constitutive STAT3 activity detected in a breast
cancer cell line is responsible for tumor cell migration [9]. In T47D
cells, IL-6/STAT axis leads to stimulation of migration [50]. STAT3
effects are in part mediated by Twist, which is required for hypoxia-
induced angiogenesis and migration [52]. In concordance with these
in vitro observations, there was a strong correlation between activated
STAT3 and Twist expression in patients' tissues. Involvement of IL-6 in
breast tumorigenesis is also evident by regulation of psoriasin in
breast tumors, a molecule whose expression is associated with tumor
aggressiveness [53]. Importantly, epithelial-to-mesenchymal tran-
sition (EMT), a process characterized with reduced expression of
E-cadherin and increased expression of markers such as vimentin or
N-cadherin, is induced in breast cancer cells by IL-6 [54]. An
involvement of the transmembrane receptor Notch and its ligand
Jagged-1 pathway in mammary carcinogenesis upon stimulation with
IL-6 was also demonstrated [55]. In concordance with all those
ﬁndings, it has been demonstrated that IL-6 is a mediator of multidrug
resistance in breast cancer [56].
For these reasons, STAT3 phosphorylation inhibitors have been
considered for growth-suppressive activity in breast cancer cells [57].
These FLLL31 and FLLL32 small molecules have been derived fromcurcumin, a compound used in cancer chemoprevention. They inhibit
STAT3 DNA binding activity, phosphorylation, and transcriptional
activity. Their potential in breast cancer therapy should be explored in
animal tumor models. In addition, the up-stream IL-6 regulator NF
kappa B could be targeted in breast cancer and it was for example
demonstrated that microRNA 146 inhibits this important transcrip-
tion factor and diminishes metastatic potential [58].
6. Interleukin-8 in breast cancer: crucial role in invasion and
angiogenesis
IL-4 is an activator of the STAT6 pathway, which was less
frequently investigated in comparison to other STAT factors. Inter-
estingly, STAT6 phosphorylation in the breast cancer cell line MCF-7
was associated with growth inhibition and induction of apoptosis
[59]. Whether these observations apply to a larger number of breast
cancer models, remains to be determined.
As expected on the basis of studies published in other cancer
types, IL-8 is in breast cancer cells associated with regulation of
proliferation and invasion [60,61]. Interestingly, although suppres-
sion of IL-8 yielded a reduced invasion in estrogen receptor-negative
cells in vitro, IL-8 suppression promoted tumor growth in nude mice
[61]. Up-regulation of estrogen receptor yielded lower IL-8 expres-
sion levels [62]. Its role in the regulation of invasion and
angiogenesis was conﬁrmed in experiments in which a neutralizing
antibody was used [63].
Similarly as other cytokines, IL-8 serum levels increase in about 2/3
of patients with advanced breast cancer. Serum IL-8 was found to be
associated with accelerated clinical progression, a higher tumor load,
and the presence of lymph node and liver metastases [64]. IL-8
secretion in benign and malignant breast tissue was enhanced by
estradiol thus suggesting that this cytokine may be a mediator of
estrogenic effects [65,66]. In addition, IL-8 levels increase by cooper-
ative action of NF-kappaB, AP-1, and C/EBP transcription factors.
Atypically methylated IL-8 gene is implicated in the metastatic
progression in breast cancer [67]. The two CpG sites were identiﬁed
upstream in the IL-8 gene in the cell lines with a higher metastatic
potential.
Because of its strong angiogenic and proinvasive effects, IL-8 is a
valid therapy target in breast cancer. Antibodies against IL-8 have
been tested in this tumor [68]. They were demonstrated to reduce the
number of metastases if combined with antibodies against the
epidermal growth factor receptor.
7. Regulation of cellular events in colon cancer by interleukin-6
Chronic colitis has been associated with carcinogenesis, how-
ever the mechanisms underlying the development of cancer have
not been completely understood [69]. Recent studies have
established the role of IL-6 and STAT3 in colitis-associated colon
cancer [70]. Regulation of STAT3 phosphorylation by IL-6 and
SOCS-3 was demonstrated in colitis and cancer [71]. High
percentage of SOCS-3-positive cells was found in ulcerative colitis
cells. The percentage of cells in which SOCS-3 is expressed
decreased during colon cancer progression. SOCS-3 itself may be
involved in regulation of proliferation and apoptosis, as described
in prostate cancer. SOCS-3 was shown to limit damage-induced
crypt hyperproliferation and tumorigenesis [72]. These observations
correlate with data showing that persistent activation of STAT3
leads to colon cancer growth [73]. Corvinus and associates showed
that a dominant-negative STAT3 mutant has an inhibitory effect on
proliferation of those cells. Similarly as in prostate cancer, it was
demonstrated that IL-6 trans-signaling promotes the in vivo tumor
progression [74]. Thus, in this tumor trans-signaling may be even
more important than signaling through the membrane receptor in
late stages of carcinogenesis.
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was shown to down-regulate Bax and increases the prosurvival form
of clusterin in colon cancer [75].
8. Similar effects of interleukin-4 and -8 in colon cancer
IL-4 is clearly implicated in regulation of cellular events in colon
cancer. It up-regulates the expression of the inhibitor of apoptosis
survivin through the STAT6 pathway [76]. When the inhibitor of the
STAT6 leﬂunomide was applied, survivin nuclear expression in-
creased. High nuclear survivin was reported in patients with good
prognosis. IL-4 receptor-alpha is a member of receptor complexes of
IL-4 and IL-13 [77] and has a critical role in promotion of in vivo
growth of colon tumors. Oncogenic effects of IL-4 were also evident in
colon cancer stem cells, in which the resistance to cytotoxic therapies
could be reversed by blockade of IL-4 signaling [78].
Consistent with previous discussions on the role of IL-8 in cancer,
there is an evidence for the oncogenic effects of the cytokine. Leptin
receptor-related immune response leads to increase in expression of
IL-8 [79]. Thus, it was demonstrated that the levels of IL-8 and its
receptor CXCR1 are higher in tumor than in normalmucosa. IL-8 could
also be induced by IL-1 or neurotensin, a neuropeptide involved in the
pathogenesis of colon inﬂammation [80,81]. Again, binding sites for
NF-kappaB, AP-1, and C/EBP in the promoter of the IL-8 gene were
required for induction of IL-8 by neurotensin. In addition, IL-8 is
produced by cancer-associated stromal ﬁbroblasts [82]. IL-8 and IL-8
receptor expression were detected in a variety of colon cancer cells
[83]. IL-8 autocrine and paracrine loops thus exist in colon cancer
[84]. Adhesion of tumor cells to endothelial cells may be regulated by
both means.
A naturally occurring antagonist of IL-8 in colon cancer is IL-10
[85]. Changes in the expression of one or both of these cytokines may
be important for the tumor development. In a recent study, IL-8 stable
colon cancer transfectants were generated. Forced expression of IL-8
leads to enhanced proliferation, migration, and angiogenesis in colon
cancer [86]. Larger tumors were formed with increased microvessel
density. Induction of IL-8 was observed in hypoxia and found to be
sufﬁcient for increased angiogenesis in colon cancer cells [87].
Anti-IL-8 therapy approaches were applied in colon cancer.
Inhibition of IL-8 may be a secondary phenomenon following an
anti-Src approach. For example, AP23846, a Src kinase inhibitor, leads
to inhibition of IL-8 expression and, subsequently, down-regulated
angiogenesis in colon cancer cells [88].
9. Conclusions and future directions
IL-6, -4, and -8 have been extensively investigated in three
common human cancers, those of prostate, breast, and colon. In most
cases, they promote tumor growth in vitro and in vivo and inhibit
apoptosis. However, in particular in the case of IL-6 it is known that
inhibition of proliferationmay be induced. This multifunctional role of
IL-6 and the transcription factor STAT3 is important because of the
therapeutic considerations in these frequent human cancers. Ther-
apeutical options against anti-IL-6 have been developed and exper-
imental evidence supports clinical studies with siltuximab. So far
some experimental studies with agents such as siltuximab have been
translated into clinical trials. Those approaches revealed a good
tolerability of the anti-IL-6 antibody, which was administrated
intravenously. However, it is of primary importance to obtain reliable
information on expression of elements of IL-6 signaling pathways and
down-stream genes in order to identify the appropriate target
population. The complex role of STAT3 in human cancers implies
that signaling networks responsible for either pro-proliferative or
anti-proliferative effects of IL-6 have to be better understood on the
basis of genomics or proteomics approaches. It is expected that anti-
cytokine therapies will provide more beneﬁt to the patients providedthat there is a better selection of them and appropriate timing during
disease development and progression.
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